Methods for diagnosing, predicting, or monitoring myocardial infarction based on methylation biomarkers
By measuring methylation levels of specific CpG regions in nucleic acids, the method addresses the limitations of existing genetic markers by providing accurate and early diagnosis and monitoring of myocardial infarction through epigenetic biomarkers, achieving high classification performance.
Patent Information
- Application Number
- KR1020240180576
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2024-09-27
- Filing Date
- 2024-12-06
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2044-12-06
AI Technical Summary
Existing genetic markers for myocardial infarction are limited in reflecting the actual onset or progression of the disease due to their reliance on fixed genetic information, failing to incorporate environmental factors, necessitating new biomarkers that can predict, diagnose, and monitor myocardial infarction more accurately.
The method involves measuring the methylation level of specific CpG regions in nucleic acids isolated from a biological sample using various techniques, including PCR and DNA microarrays, to identify differentially altered methylation patterns associated with myocardial infarction, and utilizing these markers for diagnosis, prediction, and monitoring.
The method enables objective and early prediction, diagnosis, and monitoring of myocardial infarction with improved accuracy by leveraging epigenetic changes, specifically achieving an AUC of 0.882 in classifying patients using 692 CpG sites and 0.880 with 50 CpG regions.
Smart Images

Figure 112024135519037-PAT00051_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a method for diagnosing, predicting, or monitoring myocardial infarction based on methylation biomarkers. Background Technology
[0002] Myocardial infarction (MI) is one of the leading causes of death worldwide and is a disease resulting from the complex interplay of various genetic and environmental risk factors. While various studies are currently underway for the early diagnosis and risk assessment of myocardial infarction, existing genetic markers are based on fixed genetic information and have limitations in reflecting the actual onset or progression of the disease. Therefore, there is a need for new objective and scientific indicators capable of prediction, diagnosis, and monitoring that reflect the current state by incorporating not only genetic factors but also environmental factors.
[0003] According to recent studies, epigenetic changes such as DNA methylation are influenced by environmental factors as well as genetic factors, and these changes can be utilized as useful indicators for the prediction and diagnosis of diseases. In particular, by analyzing DNA methylation changes associated with myocardial infarction and utilizing them as biomarkers, the possibility has been suggested to more accurately predict the risk of developing myocardial infarction and to enable early diagnosis and treatment.
[0004] Accordingly, the inventors compared DNA methylation patterns between patients with myocardial infarction and normal control groups through differentially methylated sites (DMSs) analysis, and completed the present invention by deriving biomarkers that exhibit significant methylation changes associated with myocardial infarction. The problem to be solved
[0005] The object of the present invention is to provide an information method for diagnosing, predicting, or monitoring myocardial infarction.
[0006] Another objective of the present invention is to provide a composition for diagnosing, predicting, or monitoring myocardial infarction.
[0007] Another objective of the present invention is to provide a kit for the diagnosis, prediction, or monitoring of myocardial infarction. means of solving the problem
[0008] In order to achieve the above objective,
[0009] The present invention provides a method for providing information for the diagnosis, prediction, or monitoring of myocardial infarction, comprising the step of measuring the methylation level of a CpG region indicated in Table 2 in nucleic acids isolated from a biological sample of an individual.
[0010] In addition, the present invention provides a composition for the diagnosis, prediction, or monitoring of myocardial infarction comprising a preparation that measures the methylation level of the CpG region indicated in Table 2.
[0011] In addition, the present invention provides a kit for diagnosing, predicting, or monitoring myocardial infarction comprising the above composition. Effects of the invention
[0012] The present invention relates to a method for diagnosing, predicting, or monitoring myocardial infarction based on methylation biomarkers. Since specific methylation markers and genes exhibiting differentially altered methylation levels in a group of patients with myocardial infarction have been identified, the method can be usefully utilized to objectively predict, diagnose, monitor, and evaluate the prognosis of myocardial infarction at an early stage. Brief explanation of the drawing
[0013] Figure 1 is a figure showing the results of verifying the myocardial infarction classification performance of epigenomic biomarkers corresponding to 692 CpG sites discovered in the present invention. Figure 2 is a figure showing the results of verifying the myocardial infarction classification performance of epigenomic biomarkers corresponding to 50 CpG regions discovered in the present invention. Specific details for implementing the invention
[0014] The present invention will be described in detail below.
[0015] The present invention provides a method for providing information for the diagnosis, prediction, or monitoring of myocardial infarction, comprising the step of measuring the methylation level of a CpG region indicated in Table 2 in nucleic acids isolated from a biological sample of an individual.
[0016] [Table 2]
[0017]
[0018]
[0019] In the present invention, the CpG region refers to a CpG region present on the DNA of a gene. The DNA of the gene is a concept that includes all of a series of constituent units necessary for expression and operably linked to one another, such as, for example, a promoter region, a protein-coding region (open reading frame, ORF), and a terminator region.
[0020] In the present invention, myocardial infarction can be diagnosed by individually analyzing the methylation level of the CpG region, but preferably, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, 24 or more, 25 or more, 26 or more, 27 or more, 28 or more, 29 or more, 30 or more, 31 or more, 32 or more, 33 or more, 34 or more, 35 or more, 36 or more, 37 or more, 38 or more, The accuracy of the diagnosis can be improved by simultaneously analyzing 39 or more, 40 or more, 41 or more, 42 or more, 43 or more, 44 or more, 45 or more, 46 or more, 47 or more, 48 or more, 49 or more, and 50 or more CpG regions.
[0021] In the present invention, the measuring step may further include the step of measuring the methylation level of one or more CpG regions selected from the group consisting of CpG regions indicated in Table 3 below. In one embodiment of the present invention, 692 differential methylation site biomarkers associated with early myocardial infarction were identified (Table 1), and 50 regions with three or more significant markers (including 202 biomarkers) were additionally selected (Table 2). Table 3 shows the remaining 490 biomarkers among the biomarkers disclosed in Table 1, excluding the biomarkers in Table 2.
[0022] [Table 3]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035] In the present invention, the nucleotide sequence of the human genome chromosome region is expressed according to the latest version, The December 2013 Human reference sequence (GRCh38); however, the specific sequence of the human genome chromosome region may be expressed in a slightly different way as genome sequence research results are updated, and the expression of the human genome chromosome region in the present invention may differ from such changes. Therefore, it is obvious that even if the expression of the human genome chromosome region expressed according to The December 2013 Human reference sequence (GRCh38) in the present invention changes differently from the present one due to an update of the human reference sequence after the filing date of the present invention, the scope of the present invention extends to the changed human genome chromosome region. Such changes are matters that anyone with ordinary knowledge in the technical field to which the present invention belongs can easily recognize.
[0036] In the present invention, the information may include determining the susceptibility of a subject to a specific disease or condition, determining whether the subject currently has a specific disease or condition, determining the prognosis of a subject with a specific disease or condition, or therametrics (e.g., monitoring the condition of an object to provide information on therapeutic efficacy).
[0037] In the present invention, the methylation refers to the attachment of a methyl group to a base constituting DNA. Preferably, the presence of methylation refers to whether methylation occurs in cytosine of a specific CpG site of the genome.
[0038] In the present invention, the methylation level, for example, in all genomic regions and some non-genomic regions, in the embodiments, the methylation state may refer to whether methylation occurs or the degree of methylation occurring in cytosines of specific CpG regions of the genome. If methylation occurs, the binding of transcription factors is interfered with, which may suppress the expression of the corresponding gene. The suppression of expression may occur relatively depending on the degree of methylation. Conversely, if non-methylation or hypomethylation occurs, the expression of a specific gene may increase. For this reason, DNA methylation is an epigenetic modification that plays a pivotal role in the regulation of gene expression, in which a methyl group (-CH3) is attached to the 5th carbon of cytosine to transform it into the form 5-methylcytosine. DNA methylation primarily occurs in the cytosine group of CpG dinucleotides. Regions where CpG dinucleotides, where DNA methylation primarily occurs, are densely concentrated are called CpG islands, which are mostly located near promoters. In addition, it is known that abnormal methylation occurs not only on CpG islands but also on CpG shores, which refer to a 2 kb range near CpG islands.
[0039] In the present invention, the measurement of the methylation level may be performed using PCR (polymerase chain reaction), methylation specific PCR, real-time methylation specific PCR, MethyLight PCR, MethyLight digital PCR, EpiTYPER, PCR using a methylated DNA-specific binding protein, quantitative PCR, DNA chip, DNA methylation microarray, immunoprecipitation using a methylated CpG binding domain or anti-methylcytosine antibody, pyrosequencing, bisulfite sequencing, Southern blot, RLGS, SNuPE, CpG island microarray, single-nucleotide primer extension, COBRA (a combined bisulfite-restriction analysis), MIRA (methylated-CpG island recovery assay), and mass spectral analysis, but is not limited thereto.
[0040] In the present invention, the step of comparing the methylation level with the methylation level of a normal control group may be further included.
[0041] In another embodiment, the step of measuring the methylation status may further include the step of comparing with a control methylation profile generated from the corresponding methylation measurement result of the corresponding marker gene of the control sample.
[0042] In another embodiment, the control methylation profile may be a model constructed by machine learning the methylation pattern of one or more of the acquired genes, and may be intended to identify a methylation pattern specific to a group of myocardial infarction patients that is different from a normal control group.
[0043] In another embodiment, the machine learning may be performed by one or more algorithms selected from the group consisting of random forest, logistic regression, support vector machine, decision tree, association rule mining, neural network, and deep learning, but is not limited thereto.
[0044] In the present invention, the subject may be a human being as a diagnostic subject, and the biological sample may be a sample separated from a patient suspected of myocardial infarction or a diagnostic subject, and may be any one selected from the group consisting of tissue, cell, blood, plasma, serum, body fluid, saliva, feces, urine, cells isolated from blood, and cell-free polynucleotides (cell-free DNA, cfDNA) of the subject, but is not limited thereto, and may be prepared by processing by a method commonly used in the technical field of the present invention.
[0045] In addition, the present invention provides a composition for the diagnosis, prediction, or monitoring of myocardial infarction comprising a preparation that measures the methylation level of the CpG region indicated in Table 3.
[0046] In the present invention, the preparation may comprise, but is not limited to, any one selected from the group consisting of a compound that modifies unmethylated cytosine bases, a methylation-sensitive restriction enzyme, a primer capable of amplifying a fragment containing a methylated base, a primer specific to an unmethylated sequence, a probe capable of hybridizing to a fragment containing a methylated base, a methylation-specific binding protein capable of binding to a methylated base, a methylation-specific binding antibody or aptamer, a sequencing primer, an SBS (sequencing by synthesis) primer, and an SBL (sequencing by ligation) primer.
[0047] As a representative example of measuring the methylation level at a specific CpG site of a gene, genomic DNA can be obtained from a patient's sample, treated with a compound that modifies non-methylated cytosine bases or a methylation-sensitive restriction enzyme, and then amplified by PCR using primers and confirmed the presence or absence of the amplified product.
[0048] In the present invention, the compound that modifies the unmethylated cytosine base may be a bisulfite or a salt thereof, but is not limited thereto. A method of detecting whether methylation has occurred by modifying an unmethylated cytosine residue using such a bisulfite is widely known in the art.
[0049] In the present invention, the methylation-sensitive restriction enzyme is a restriction enzyme capable of specifically detecting methylation of a CpG region, and may be a restriction enzyme containing CG as a recognition site. The methylation-sensitive restriction enzyme is well known in the art and, preferably, Acc III, Ban I, BstN I, Msp I, Xma I, Acc II, Ava , Sma I, Sac II, Eag I, Hpa II, BssH II, BstU I or Not It may be I, but is not limited to this.
[0050] The formulation of the present invention may include a primer capable of amplifying a fragment containing a methylated base, and a primer specific to a non-methylated sequence.
[0051] In the present invention, a primer refers to a short nucleic acid sequence having a short free 3-terminal hydroxyl group, capable of forming base pairs with a complementary template, and functioning as a starting point for template strand replication. The primer can initiate DNA synthesis in the presence of a reagent for a polymerization reaction (i.e., DNA polymerase or reverse transcriptase) and four different nucleoside triphosphates at an appropriate buffer solution and temperature. Additionally, the primer may incorporate additional features that do not alter the basic properties of the primer acting as a starting point for DNA synthesis, such as being sense and antisense nucleic acids having a sequence of 7 to 50 nucleotides.
[0052] The primers of the present invention can be preferably designed according to the sequence of a specific CpG site to be analyzed for methylation status, and may be a primer pair capable of specifically amplifying cytosine that is methylated and not modified by bisulfite, and a primer pair capable of specifically amplifying cytosine that is not methylated and is modified by bisulfite.
[0053] The formulation of the present invention may include a methylation-specific binding antibody.
[0054] In the present invention, a methylation-specific binding antibody refers to an antibody that specifically binds to methylated bases in DNA. Specifically, examples include antibodies that have the property of recognizing and binding to methylated cytosines in DNA chains, such as antibodies against methyl cytosine. Additionally, among commercially available methylated DNA antibodies, there may be antibodies capable of specifically recognizing and specifically binding to DNA in a methylated state as described herein.
[0055] Methylated DNA antibodies can be produced by conventional methods using methylated bases, methylated DNA, etc. as antigens. For example, to produce a methylcytosine antibody, antibodies can be produced using 5-methylcytidine, 5-methylcytosine, or DNA containing 5-methylcytosine as antigens, and then specific binding to methylcytosine in the DNA can be selected as an indicator.
[0056] In the above composition, specific descriptions of identical components such as "CpG region", "biological sample", "methylation", and "methylation level" are as described above.
[0057] In addition, the present invention provides a kit for diagnosing, predicting, or monitoring myocardial infarction comprising the composition for diagnosing, predicting, or monitoring myocardial infarction.
[0058] In the present invention, the kit may include a compartmentalized carrier means for holding a sample and a preparation capable of measuring the methylation level of the gene. For example, the kit may include one or more containers, including a compartmentalized carrier means for holding a sample, a first container containing a preparation that sensitively cleaves unmethylated cytosine, a second container containing a primer for amplifying CpG-containing nucleic acid, and a third container containing a means for detecting the presence of cleaved or uncleaved nucleic acid.
[0059] Specifically, the kit consists of one or more different component compositions, solutions, or devices suitable for the analysis method. For example, the kit may be an RT-PCR (Reverse transcription polymerase chain reaction) kit, a DNA chip kit, an ELISA (Enzyme-linked immunosorbent assay) kit, a protein chip kit, or a rapid kit. In addition to the above preparations, the kit may additionally include polymerase agarose, a buffer solution required for electrophoresis, etc.
[0060] In the above kit, specific descriptions of identical components such as "CpG region", "biological sample", "methylation", and "methylation level" are as described above.
[0061] The present invention will be described in more detail below through examples. These examples are intended solely to explain the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the invention.
[0062] <Example 1> Selection of Epigenomic Markers Associated with Myocardial Infarction
[0063] <1-1> Data Collection and Methylation Data Production
[0064] 298 early-stage myocardial infarction patients collected from hospitals and 247 healthy individuals collected from the Korean Genome Project were enrolled as subjects in a study according to an embodiment of the present invention. The early-stage myocardial infarction patient group and the healthy individual group were composed so as not to differ in gender and age ratios. DNA was extracted from the collected blood samples using the DNeasy Blood and Tissue Kit, and a library was created using the SureSelectXT Methyl-Seq Target Enrichment System Kit for methylation data decoding. Raw data was generated using the Illumina NovaSeq 6000 platform (Illumina).
[0065] <1-2> Selection of Myocardial Infarction-Associated Epigenomic Markers via Differentially Methylated Site Analysis
[0066] In the present invention, a logistic regression model including sex and age as covariates was implemented using the methylKit package (v.1.20.0) to identify differential methylation site biomarkers associated with early myocardial infarction. Analysis was performed using CpGs with a minimum sequencing depth of 10 or greater, and CpGs below this threshold were treated as missing values (NA). 873,124 CpGs with values were identified in all samples, and McCullagh and Nelder (MN) correction was applied after the logistic regression model to improve the accuracy of differential methylation sites (DMS) and eliminate false positive results.
[0067] Significant differential methylation site biomarkers were identified based on a false discovery rate (FDR; Benjamini-Hochberg corrected) adjusted value of 0.05 or less, and a mean difference in methylation levels between the patient group and the control group of at least 10%. To reduce sampling bias, 10-fold cross-validation was performed, and 692 differential methylation site biomarkers identified as consistently significant across all 10 sets were defined as a set of significant methylation biomarkers associated with myocardial infarction (Table 1).
[0068] [Table 1]
[0069]
[0070] The present invention focused on 50 regions composed of significant methylation biomarkers associated with myocardial infarction clustered in specific areas. These regions were defined iteratively by merging statistically significant biomarkers, where the distance between adjacent biomarkers is within 125 base pairs. Therefore, within these specific regions, biomarkers within the same area may be located at a distance of more than 125 base pairs. Finally, the 50 regions were selected as areas where three or more statistically significant biomarkers for myocardial infarction exist (Table 2).
[0071] [Table 2]
[0072]
[0073]
[0074] <Example 2> Performance Verification of Myocardial Infarction-Associated Epigenomic Markers
[0075] <2-1> Performance Verification of 692 CpG Sites Associated with Myocardial Infarction
[0076] The performance of classifying myocardial infarction patients using the myocardial infarction-associated epigenomic markers in Table 1 above was verified using a machine learning algorithm.
[0077] Specifically, the data collected in this invention was divided into a 7:3 ratio to train a classification model on the training set and to verify the performance of the model on the validation set. At this time, methylation values at each differential methylation location of myocardial infarction patients were learned based on a logistic regression classification model.
[0078] As a result, as shown in Figure 1, it was verified that the epigenomic biomarkers corresponding to the 692 CpG sites discovered in the present invention can classify patients with myocardial infarction with an AUC (Area Under Curve) of 0.882.
[0079] <2-2> Performance Verification of 50 CpG Regions Associated with Myocardial Infarction
[0080] The performance of classifying myocardial infarction patients was verified using 50 regions of the myocardial infarction-associated epigenomic markers in Table 2.
[0081] The specific experimental method was carried out in the same manner as in Example <2-1>.
[0082] As a result, as shown in Figure 2, it was verified that the epigenetic biomarkers corresponding to the 50 CpG regions discovered in the present invention can classify patients with myocardial infarction with an AUC of 0.880.
[0084] Although exemplary embodiments of the present invention have been described above in relation to the preferred embodiments mentioned above, various modifications and variations are possible without departing from the essence and scope of the invention. Accordingly, such modifications and variations are included insofar as they fall within the essence of the invention in the appended claims.
Claims
Claim 1 A method for providing information for the diagnosis, prediction, or monitoring of myocardial infarction, comprising the step of measuring the methylation level of a CpG region indicated by Table 2 below in nucleic acids isolated from a biological sample of an individual.[Table 2] Claim 2 The method of claim 1, characterized in that the measuring step further comprises the step of measuring the methylation level of one or more CpG regions selected from the group consisting of CpG regions indicated in Table 3 below.[Table 3] Claim 3 In claim 1, the measurement of the methylation level is characterized by being performed by a method selected from the group consisting of PCR (polymerase chain reaction), methylation-specific PCR, real-time methylation-specific PCR, MethyLight PCR, MethyLight digital PCR, EpiTYPER, PCR using a methylated DNA-specific binding protein, quantitative PCR, DNA chip, DNA methylation microarray, immunoprecipitation using a methylated CpG binding domain or anti-methylcytosine antibody, pyrosequencing, bisulfite sequencing, southern blot, RLGS (restriction landmark genomic scanning), SNuPE (single nucleotide primer extension), CpG island microarray, COBRA (a combined bisulfite-restriction analysis), MIRA (methylated-CpG island recovery assay), and mass spectral analysis. The method of doing. Claim 4 A method according to claim 1, further comprising the step of comparing the methylation level with the methylation level of a normal control group. Claim 5 A method according to claim 1, wherein the biological sample is selected from the group consisting of tissue, cells, blood, plasma, serum, body fluid, saliva, feces, urine, cells isolated from blood, and cell-free polynucleotides (cfDNA) derived from a patient suspected of having myocardial infarction or a patient subject to diagnosis. Claim 6 A composition for the diagnosis, prediction, or monitoring of myocardial infarction, comprising a preparation for measuring the methylation level of the CpG region indicated by Table 2 of claim 1. Claim 7 A composition according to claim 6, characterized in that the above formulation further comprises a formulation for measuring the methylation level of one or more CpG regions selected from the group consisting of CpG regions indicated by Table 3 of claim 2. Claim 8 A composition according to claim 6, wherein the preparation comprises any one selected from the group consisting of a compound that modifies unmethylated cytosine bases, a methylation-sensitive restriction enzyme, a primer capable of amplifying a fragment containing a methylated base, a primer specific to an unmethylated sequence, a probe capable of hybridizing to a fragment containing a methylated base, a methylation-specific binding protein capable of binding to a methylated base, a methylation-specific binding antibody or aptamer, a sequencing primer, an SBS (sequencing by synthesis) primer, and an SBL (sequencing by ligation) primer. Claim 9 A composition according to claim 8, characterized in that the compound modifying the non-methylated cytosine base is bisulfite or a salt thereof. Claim 10 In claim 8, the methylation-sensitive restriction enzyme is Acc III, Ban I, Bst NI, Msp I, Xma I, Acc II, Ava , Sma I, Sac II, Eag I, Hpa II, BssH II, BstU I or Not A composition characterized by including I. Claim 11 Myocardial infarction comprising the composition of claim 6 or 7 Kit for diagnosis, prediction, or monitoring. Claim 12 In claim 11, the kit comprises one or more of the following: a first container containing a preparation for sensitively cleaving nonmethylated cytosine; a second container containing a primer for amplifying CpG-containing nucleic acid; and a third container containing a means for detecting the presence of cleaved or uncleaved nucleic acid; and a compartmentalized carrier means for holding a sample.
Citation Information
Patent Citations
Method for providing information for predicting prognosis of acute coronary syndrome and composition therefor
KR1020210112774A
Genetic polymorphisms associated with myocardial infarction and uses thereof
KR1020230150127A
